PolyPid (PYPD) Aperçu de l'action
PolyPid Ltd, une société biopharmaceutique qui développe des produits thérapeutiques ciblés, administrés localement et à libération prolongée en utilisant sa technologie exclusive de matrice d'encapsulation polymère-lipide (PLEX) pour répondre à des besoins médicaux non satisfaits. Plus de détails
| Score flocon de neige | |
|---|---|
| Évaluation | 0/6 |
| Croissance future | 3/6 |
| Performances passées | 0/6 |
| Santé financière | 3/6 |
| Dividendes | 0/6 |
Récompenses
Analyse des risques
PYPD Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
PolyPid Ltd. Concurrents
Historique des prix et performances
| Historique des cours de bourse | |
|---|---|
| Prix actuel de l'action | US$4.34 |
| Plus haut sur 52 semaines | US$5.12 |
| Plus bas sur 52 semaines | US$2.44 |
| Bêta | 1.41 |
| Variation sur 1 mois | 0.70% |
| Variation sur 3 mois | -7.27% |
| Variation sur 1 an | 52.28% |
| Variation sur 3 ans | -59.81% |
| Variation sur 5 ans | -98.42% |
| Évolution depuis l'introduction en bourse | -99.24% |
Nouvelles et mises à jour récentes
Long Regulatory And Commercial Risks Around Lead Therapy Could Eventually Reward Patient Holders
Catalysts About PolyPid PolyPid is a biopharmaceutical company developing locally and systemically delivered, long acting therapies based on its proprietary drug delivery technology, with D PLEX100 for prevention of surgical site infections as its lead program. What are the underlying business or industry changes driving this perspective?
Regulatory Tailwinds And Extended Release Platform Will Shape A Stronger Long Term Outlook
Catalysts About PolyPid PolyPid is a biopharmaceutical company focused on extended release drug delivery products such as D-PLEX100 for prevention of surgical site infections and longer acting metabolic therapies using its Kynatrix technology. What are the underlying business or industry changes driving this perspective?Recent updates
Long Regulatory And Commercial Risks Around Lead Therapy Could Eventually Reward Patient Holders
Catalysts About PolyPid PolyPid is a biopharmaceutical company developing locally and systemically delivered, long acting therapies based on its proprietary drug delivery technology, with D PLEX100 for prevention of surgical site infections as its lead program. What are the underlying business or industry changes driving this perspective?Regulatory Tailwinds And Extended Release Platform Will Shape A Stronger Long Term Outlook
Catalysts About PolyPid PolyPid is a biopharmaceutical company focused on extended release drug delivery products such as D-PLEX100 for prevention of surgical site infections and longer acting metabolic therapies using its Kynatrix technology. What are the underlying business or industry changes driving this perspective?
Long Acting Drug Delivery And Metabolic Health Pipeline Will Transform Future Prospects
Catalysts About PolyPid PolyPid is a clinical stage biopharmaceutical company focused on long acting drug delivery products such as D PLEX100 for prevention of surgical site infections and a GLP 1 receptor agonist program for metabolic disease. What are the underlying business or industry changes driving this perspective?Is PolyPid (NASDAQ:PYPD) A Risky Investment?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...PolyPid set to cut 20% jobs
PolyPid (NASDAQ:PYPD) announced on Thursday a cost reduction plan, including a 20% job cut across all departments as it expects the actions to extend tits cash runway into Q3 2023. The company expects to discuss regulatory pathway for D-PLEX100 for prevention of surgical site infections in abdominal surgery with U.S. and EU regulatory authorities in Q1 2023. As of February 28, the company had 78 full-time employees.PolyPid's surgical site infections treatment eligible for marketing nod submission in EU
PolyPid (NASDAQ:PYPD) on Wednesday said it had got confirmation from Europe's drug regulator that its D-PLEX100 product candidate for the treatment of surgical site infections was eligible to be submitted for a marketing authorization. The company said the product candidate was eligible for the European Medicines Agency's (EMA) centralized procedure under the therapeutic innovation criteria. "The centralized procedure allows the submission of a single marketing application to the EMA that, if approved, enables the product to be marketed in all EU member states as well as in Iceland, Liechtenstein and Norway," PYPD said in a statement. The company is currently evaluating its recently concluded phase 3 trial which evaluated D-PLEX100 for the prevention of surgical site infections in abdominal surgery. PYPD said it intends to discuss the data from the late-stage trial and potential next steps with U.S. and EU regulators in Q1 2023. PolyPid (PYPD) stock +1.2% to $1.10 in morning trading.PolyPid sheds 75% as lead candidate fails in Phase 3 trial for post-surgical infections
PolyPid Ltd. (NASDAQ:PYPD) dropped ~75% in value in the pre-market trading Friday after the Israeli company announced that its lead candidate D-PLEX100 did not meet the main goal in a Phase 3 trial for the prevention of surgical site infections ((SSIs)) in abdominal surgery. The SHIELD I was designed to evaluate the joint administration of D-PLEX100 standard of care (SoC) against SoC alone arm in 970 patients out of whom 488 were part of the D-PLEX100 treatment arm and 489 were in the control arm. The trial did not achieve the primary endpoint of reduction in surgical site infections and mortality, the company said noting that in the Intent to Treat (ITT) population, D-PLEX100 and SoC (n=485) led to 23% decrease in SSIs and mortality compared to SoC alone (n=489) (p=0.1520).PolyPid GAAP EPS of -$1.23 misses by $0.60
PolyPid press release (NASDAQ:PYPD): Q2 GAAP EPS of -$1.23 misses by $0.60. As of June 30, 2022, the Company had cash and cash equivalents and deposits in the amount of $23.8 million, not including the second tranche of $2.5 million from the Kreos Capital VI (Expert Fund) LP (“Kreos”) loan, which was drawn in July 2022.PolyPid to get $2.6M upfront under license deal with Advanz for D-PLEX in Europe
PolyPid (NASDAQ:PYPD) signed an exclusive licensing agreement for its lead drug candidate D-PLEX100 in Europe with U.K.-based Advanz Pharma (OTCPK:CXRXF). D-PLEX100 is used for preventing surgical site infections (SSIs) in abdominal and cardiac surgeries, in Europe. Under the agreement, PolyPid will receive $2.6M upfront and development-related milestones of up to $20.9M. Upon commercialization, PolyPid will receive up to $89M in sales-related milestones, the company said in an Aug. 3 press release. In addition, PolyPid will also supply D-PLEX100 to Advanz for a transfer price and will be entitled to royalties on net sales in double-digit percentages of up to mid-twenties. "Advanz Pharma's expertise in marketing hospital-based therapies, combined with its significant resources and relationships in the region, will prove invaluable in expanding access to D-PLEX100 and delivering this much-needed therapy, if approved, to patients," said PolyPid's CEO Dikla Czaczkes Akselbrad.PolyPid: Strong Pipeline, Close Catalysts
PolyPid develops a platform technology to provide locally controlled and continuous delivery of medications. Lead product candidate D-PLEX100 is investigated for the prevention of sternal and abdominal surgical site infections serving a huge market. Meaningful interim results and topline data from pivotal Phase 3 SHIELD I clinical trial will soon be published. Measured in terms of the clinical benefit of D‑PLEX100 and its estimated market size, PolyPid is clearly undervalued at present in our view.Will PolyPid (NASDAQ:PYPD) Spend Its Cash Wisely?
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...Here's Why We're Watching PolyPid's (NASDAQ:PYPD) Cash Burn Situation
We can readily understand why investors are attracted to unprofitable companies. For example, although...We Think PolyPid (NASDAQ:PYPD) Can Afford To Drive Business Growth
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...Here's Why We're Not Too Worried About PolyPid's (NASDAQ:PYPD) Cash Burn Situation
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Rendement pour les actionnaires
| PYPD | US Pharmaceuticals | US Marché | |
|---|---|---|---|
| 7D | -3.1% | -1.9% | 2.2% |
| 1Y | 52.3% | 33.5% | 31.1% |
Rendement vs Industrie: PYPD a dépassé le secteur US Pharmaceuticals qui a rapporté 33.5 % au cours de l'année écoulée.
Rendement vs marché: PYPD a dépassé le marché US qui a rapporté 31.1 % au cours de l'année écoulée.
Volatilité des prix
| PYPD volatility | |
|---|---|
| PYPD Average Weekly Movement | 5.4% |
| Pharmaceuticals Industry Average Movement | 9.9% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.1% |
| 10% least volatile stocks in US Market | 3.2% |
Cours de l'action stable: PYPD n'a pas connu de volatilité de prix significative au cours des 3 derniers mois par rapport au marché US.
Volatilité au fil du temps: La volatilité hebdomadaire de PYPD ( 5% ) est restée stable au cours de l'année écoulée.
À propos de l'entreprise
| Fondée | Salariés | PDG | Site web |
|---|---|---|---|
| 2008 | 72 | Dikla Czaczkes Akselbrad | www.polypid.com |
PolyPid Ltd. est une société biopharmaceutique qui développe des produits thérapeutiques ciblés, administrés localement et à libération prolongée en utilisant sa technologie exclusive de matrice d'encapsulation polymère-lipide (PLEX) pour répondre à des besoins médicaux non satisfaits. Son principal produit candidat est le D-PLEX100, qui fait l'objet d'un essai pivot de confirmation de phase 3 pour la prévention des infections du site opératoire (ISO) chez les patients subissant une chirurgie abdominale colorectale avec de grandes incisions. La société développe également OncoPLEX, qui est au stade préclinique pour le traitement du cancer intra-tumoral.
PolyPid Ltd. Résumé des fondamentaux
| PYPD statistiques fondamentales | |
|---|---|
| Capitalisation boursière | US$83.58m |
| Bénéfices(TTM) | -US$34.17m |
| Recettes(TTM) | n/a |
Le site PYPD est-il surévalué ?
Voir Juste valeur et analyse de l'évaluationBénéfices et recettes
| PYPD compte de résultat (TTM) | |
|---|---|
| Recettes | US$0 |
| Coût des recettes | US$0 |
| Marge brute | US$0 |
| Autres dépenses | US$34.17m |
| Les revenus | -US$34.17m |
Derniers bénéfices déclarés
Dec 31, 2025
Prochaine date de publication des résultats
May 13, 2026
| Résultat par action (EPS) | -1.79 |
| Marge brute | 0.00% |
| Marge bénéficiaire nette | 0.00% |
| Ratio dettes/capitaux propres | 9.0% |
Quelles ont été les performances à long terme de PYPD?
Voir les performances historiques et les comparaisonsAnalyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/05/11 01:30 |
| Cours de l'action en fin de journée | 2026/05/11 00:00 |
| Les revenus | 2025/12/31 |
| Revenus annuels | 2025/12/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github; nous proposons également des guides expliquant comment utiliser nos rapports et des tutoriels sur Youtube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
PolyPid Ltd. est couverte par 8 analystes. 4 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Balaji Prasad | Barclays |
| Balaji Prasad | Barclays |
| Gary Nachman | BMO Capital Markets Equity Research |